Table 7.
Ongoing trials evaluating ruxolitinib combinations in patients with myelofibrosis.
| Partner drug class | Specific agent | Clinicaltrials.gov identifier |
|---|---|---|
| Histone deacetylase inhibitor | Panobinostat | NCT01693601 |
| Panobinostat | NCT01433445 | |
| Pracinostat | NCT02267278 | |
| Phosphatidylinositol-3-kinase (delta isoform) inhibitor | INCB050465 | NCT02718300 |
| Idelalisib | NCT02436135 | |
| TGR1202 | NCT02493530 | |
| Immunomodulatory agent | Thalidomide | NCT03069326 |
| Lenalidomide | NCT01375140 | |
| Pomalidomide | NCT01644110 | |
| Janus kinase 1 inhibitor | Itacitinib | NCT03144687 |
| BH3-mimetic | Navitoclax | NCT03222609 |
| Hedgehog (smoothened) inhibitor | Vismodegib | NCT02593760 |
| Sonidegib | NCT01787552 | |
| Cyclin-dependent kinase 4/6 inhibitor and PIM kinase inhibitor | Ribociclib and PIM447 | NCT02370706 |
| Androgen | Danazol | NCT01732445 |
| Interferon | Pegylated interferon alfa 2a | NCT02742324 |
| Hypomethylating agent | Azacitidine | NCT01787487 |
| Activin receptor ligand trap | Sotatercept | NCT01712308 |
| Luspatercept | NCT03194542 | |
| Erythropoiesis stimulating agent | Any (observational study) | NCT03208803 |